Samsung Biologics announces financial results for the third quarter of 2024
Samsung Biologics reported consolidated revenue of KRW 1.2 trillion and operating profit of KRW 338.6 billion for the third quarter of fiscal year 2024. The company emphasized its commitment to providing high-quality solutions and expanding its global partnerships to enhance value for clients. In Q3’24, Samsung Biologics achieved a 15% increase in revenue compared to … Read more